Production (Stage)
Edgewise Therapeutics, Inc.
EWTX
$15.29
-$0.13-0.84%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 0.35% | 11.69% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.92% | 12.63% | |||
| Operating Income | -0.92% | -12.63% | |||
| Income Before Tax | -2.86% | -16.21% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -2.86% | -16.21% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.86% | -16.21% | |||
| EBIT | -0.92% | -12.63% | |||
| EBITDA | -1.07% | -12.71% | |||
| EPS Basic | -2.44% | -15.09% | |||
| Normalized Basic EPS | -2.41% | -15.08% | |||
| EPS Diluted | -2.44% | -15.09% | |||
| Normalized Diluted EPS | -2.41% | -15.08% | |||
| Average Basic Shares Outstanding | 0.43% | 0.97% | |||
| Average Diluted Shares Outstanding | 0.43% | 0.97% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||